Biotechnology company Odyssey Therapeutics has announced the closing of a $101 million Series C financing round led by Ascenta Capital. Odyssey’s total capital raised since inception now stands at $487 million. The money will be used to support the advancement of multiple programs into clinical studies and further investment in discovery to drive therapeutic innovation.
Based in Boston, Odyssey aims to bring safe and effective medicines to patients with serious diseases. The company has developed a comprehensive drug discovery and development platform that combines computational and experimental technologies. Since its founding in 2021, Odyssey has made significant progress in advancing multiple pre-clinical programs in immunology and oncology.
Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital, and former chief financial officer at Moderna, will join Odyssey’s board of directors. With the latest funding round and the addition of Dr. Kim to the board, Odyssey will continue to develop its pipeline of precision immunomodulators and oncology medicines.
